Search Result

Results for "

type-II diabetes

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) AMPK (1) Amylases (2) Amylin Receptor (2) Apoptosis (4) Biochemical Assay Reagents (1) Calcium Channel (1) Cytochrome P450 (1) Endogenous Metabolite (5) Free Fatty Acid Receptor (10) Fungal (3) GLP Receptor (5) Glycosidase (4) Interleukin Related (1) IPK Superfamily (1) IRE1 (1) Isotope-Labeled Compounds (1) Lipoxygenase (2) MAGL (1) Mitochondrial Metabolism (1) Monoamine Oxidase (1) NOD-like Receptor (NLR) (1) Phosphatase (2) Phosphodiesterase (PDE) (2) PPAR (5) Reactive Oxygen Species (ROS) (1) Reference Standards (4) SGLT (1) Stearoyl-CoA Desaturase (SCD) (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (1) Endocrinology (2) Infection (4) Inflammation/Immunology (9) Metabolic Disease (41) Neurological Disease (6)
Oligonucleotides:	Cationic Lipids (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W011303

Phytosphingosine 4 Publications Verification 4-Hydroxysphinganine	Apoptosis Endogenous Metabolite Fungal Free Fatty Acid Receptor	Infection Metabolic Disease Inflammation/Immunology Cancer
Phytosphingosine is a phospholipid with anti-inflammatory, antibacterial, and anti-cancer activities, which can induce apoptosis. Phytosphingosine is an immune regulator and can be used in the study of inflammatory skin diseases. Phytosphingosine is also an activator of GPR120 with an IC₅₀ value of 33.4 μM and can be used in the study of type II diabetes .

HY-13525

CP-91149 Maximum Cited Publications 8 Publications Verification	Biochemical Assay Reagents	Metabolic Disease Cancer
CP-91149 is a GP (glycogen phosphorylase) inhibitor. CP-91149 promotes glycogen resynthesis, but not its overaccumulation. CP-91149 has the potential for Type II (insulin-dependent) diabetes study .

HY-177295

Naperiglipron LY3549492	GLP Receptor Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Naperiglipron (LY3549492) is an orally active Glucagon-like peptide 1 receptor (GLP-1R) agonist with an EC₅₀ of 1.14 nM for hGLP-1R. Naperiglipron significantly decreases the level of blood glucose in GLP-1R knock-in mouse models. Naperiglipron inhibits PDE10A1 enzyme activity (IC₅₀: 7.43 μM) with a weak hERG inhibitory activity. Naperiglipron can be used for type II diabetes mellitus (T2DM) and obesity research .

HY-113166

Dodecanoylcarnitine 1 Publications Verification (-)-Lauroylcarnitine	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Dodecanoylcarnitine ((-)-Lauroylcarnitine) is a medium long-chain acylcarnitine, an intermediate product in key energy metabolic pathways of fatty acid β-oxidation and amino acids catabolism. The abnormal decrease in the Dodecanoylcarnitine levels indicats that mitochondrial fuel metabolism, including fatty acid oxidation is significantly disturbed. Changes in plasma concentrations of Dodecanoylcarnitine are not only associated with type II diabetes, but also with pre-diabetes status. Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease. Dodecanoylcarnitine deomonstrates high sensitivities and specificities in predicting asthma. Combined model of Decanoylcarnitine (HY-113069), Dodecanoylcarnitine, PC (16:0/0:0), and Asp Arg Pro can be used as a potential biomarker for the diagnosis of Yin-deficiency-heat syndrome .

HY-109500

Masoprocol meso-Nordihydroguaiaretic acid; meso-NDGA	Lipoxygenase	Metabolic Disease Cancer
Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .

HY-16619

AM-5262	Free Fatty Acid Receptor	Metabolic Disease
AM-5262 is a GPR40 full agonist with an EC₅₀ value of 0.081 μM. AM-5262 can be used for the research of type II diabetes .

HY-114520

TT01001	Monoamine Oxidase Mitochondrial Metabolism Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease
TT01001 is a selective and orally active mitoNEET agonist and a monoamine oxidase B (MAO-B) inhibitor (IC₅₀ = 8.84 μM). TT01001 does not activate PPARγ but interacts with MitoNEET. TT01001 attenuates oxidative stress and neuronal apoptosis by preventing mitoNEET-mediated mitochondrial dysfunction. TT01001 improves type II diabetes and ameliorates mitochondrial function of mice. TT01001 can used for the studies of type II diabetes and neurological disorders .

HY-120160

Darglitazone CP-86325	PPAR	Neurological Disease Metabolic Disease
Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .

HY-153530

LI-2242	IPK Superfamily	Neurological Disease Metabolic Disease
LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC₅₀ values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders .

HY-P4767

Amylin (1-13) (human)	Amylin Receptor	Metabolic Disease
Amylin (1-13) (human) is a fragment and a residues within amyloid cores of Amylin (human IAPP). Amylin is a glucose-regulating hormone, deposits as amyloid fibrils in condition of type II diabetes (T2D). Amylin (1-13) (human) has no effect on firbl formation, as it cannot form fibrils by itself .

HY-112603

AP5	Free Fatty Acid Receptor	Metabolic Disease
AP5 is a potent, orlly active, and selective GPR40 receptor agonist with a positive allosteric modulation of endogenous ligand (AgoPAM). AP5 demonstrates rat and human inositol monophosphate (IP1) EC₅₀ values of 0.49 nM and 0.8 nM against the GPR40 receptor, respectively. AP5 has the potential for type II diabetes research .

HY-14728

Aleglitazar R1439; RO0728804	PPAR	Metabolic Disease
Aleglitazar (R1439) is a potent dual PPARα/γ agonist, with IC₅₀s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes .

HY-139077

SCD1 inhibitor-3	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease Cancer
SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer .

HY-153335

Enpp-1-IN-16	Phosphodiesterase (PDE)	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders .

HY-P2501

Amylin (8-37), human	Amylin Receptor	Metabolic Disease
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus .

HY-154972

α-Amylase/α-Glucosidase-IN-3	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-3 (Compound 17) is an α-Amylase/α-Glucosidase dual inhibitor, with IC₅₀s of 0.70 μM and 1.10 μM. α-Amylase/α-Glucosidase-IN-3 can be used for research of type-II diabetes mellitus .

HY-114632

Oxeglitazar	PPAR	Metabolic Disease
Oxeglitazar is an orally active compound that can be used for the research of type II diabetes .

HY-141653

MK-8666 tromethamine	Free Fatty Acid Receptor	Metabolic Disease
MK-8666 (tromethamine) is a GPR40 agonist. MK-8666 (tromethamine) can be used in the research of type II diabetes .

HY-161429

Antidiabetic agent 5	Amylases Glycosidase	Metabolic Disease
Antidiabetic agent 5 (compound S1) is a antidiabetic agent. Antidiabetic agent 5 inhibits the activity of α-glucosidase and α-amylase with IC₅₀ values of 3.91，8.89 μM，respectively. Antidiabetic agent 5 decreases sugar levels. Antidiabetic agent 5 has the potential for the research of type-II diabetes .

HY-18903

DSA8	IRE1	Metabolic Disease Cancer
DSA8 is a type II kinase inhibitor with IRE1 RNase modulating activity. DSA8 can be used for the research of cancer, metabolic disease, suah as diabetes .

HY-120223

BMS-196085	Adrenergic Receptor	Metabolic Disease
BMS-196085 is an orally active, potent and selective full agonist against human β₃ adrenergic receptor with a K_i value of 21 nM. BMS-196085 also has partial agonist activity at the β₁ receptor. BMS-196085 is promising for research of obesity and type-II diabetes .

HY-177296

GPR40 agonist 8	Free Fatty Acid Receptor Calcium Channel	Metabolic Disease
GPR40 agonist 8 (Compound 2) is a GPR40 agonist with an EC₅₀ of 5 nM for hGPR40 Ca ²⁺. GPR40 agonist 8 can be used in the research of diseases such as Type II diabetes and obesity .

HY-108196

PTP1B-IN-15	Phosphatase	Endocrinology
PTP1B-IN-15 is a potent and selective inhibitor of protein tyrosine phosphatase 1B (PTP1B). PTP1B-IN-15 has the potential for the research of type II diabetes and obesity .

HY-W011303R

Phytosphingosine (Standard) 4-Hydroxysphinganine (Standard)	Reference Standards Apoptosis Endogenous Metabolite Fungal Free Fatty Acid Receptor	Infection Metabolic Disease Inflammation/Immunology Cancer
Phytosphingosine (Standard) is the analytical standard of Phytosphingosine. This product is intended for research and analytical applications. Phytosphingosine is a phospholipid with anti-inflammatory, antibacterial, and anti-cancer activities, which can induce apoptosis. Phytosphingosine is an immune regulator and can be used in the study of inflammatory skin diseases. Phytosphingosine is also an activator of GPR120 with an IC50 value of 33.4 μM and can be used in the study of type II diabetes[1][2][3][4].

HY-14810

Atigliflozin AVE-2268	SGLT	Metabolic Disease
Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC₅₀s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus .

HY-120886

GW 2433	PPAR	Metabolic Disease
GW 2433 is a dual PPARα and PPARδ agonist. GW 2433 has the potential for the study of type II diabetes and dyslipidemia .

HY-111353

GPR120 Agonist 2	Free Fatty Acid Receptor	Metabolic Disease
GPR120 Agonist 2 (example 206) is a GPR120 agonist that can be uesd for the study of type II diabetes and diseases associated with poor glycemic control .

HY-P10312

SPN009	GLP Receptor	Metabolic Disease
SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC₅₀ of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models .

HY-110178

WWL123	MAGL	Inflammation/Immunology
WWL123, a carbamate-based compound, is a potent and selective ABHD6 inhibitor. WWL123 can be used for research of inflammation, metabolic disorders (obesity and type II diabetes mellitus) and epilepsy .

HY-162042

AMPK activator 14	AMPK	Metabolic Disease
AMPK activator 14 (compound 32) is an orally active AMPK activator. AMPK activator 14 decreases fasted glucose and insulin levels in a db/db mouse model of Type II diabetes .

HY-120160A

Darglitazone Sodium CP 86325 Sodium	PPAR	Neurological Disease Metabolic Disease
Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective PPAR-γ (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .

HY-147964

α-Glucosidase-IN-9	Glycosidase	Metabolic Disease
α-Glucosidase-IN-9 (compound 7) is a potent α-glucosidase inhibitor, with an IC₅₀ of 55.6 μM. α-Glucosidase-IN-9 can be used for type II diabetes research .

HY-147965

α-Glucosidase-IN-10	Glycosidase	Metabolic Disease
α-Glucosidase-IN-10 (compound 13) is a potent α-glucosidase inhibitor, with an IC₅₀ of 92.7 μM. α-Glucosidase-IN-10 can be used for type II diabetes research .

HY-160628

GPR120 Agonist 4	Free Fatty Acid Receptor	Metabolic Disease
GPR120 Agonist 4 (example 1) is a GPR120 agonist，with the EC₅₀ values of 1 μM and 0.35 μM for β-arrestin A and Calcium A. GPR120 Agonist 4 can be used for the research of type II diabetes mellitus .

HY-162979

GLP-1R agonist 25	GLP Receptor	Metabolic Disease
GLP-1R agonist 25 (compound 13) is a GLP1-R agonist, with an EC₅₀ of 0.167 nM. GLP-1R agonist 25 can be used in type II diabetes research .

HY-109500R

Masoprocol (Standard) meso-Nordihydroguaiaretic acid (Standard); meso-NDGA (Standard)	Lipoxygenase Reference Standards	Metabolic Disease Cancer
Masoprocol (Standard) is the analytical standard of Masoprocol. This product is intended for research and analytical applications. Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .

HY-N9153A

Guaiacylglycerol-8-O-4'-(sinapyl alcohol) ether	Others	Metabolic Disease
Guaiacylglycerol-8-O-4'-(sinapyl alcohol) ether is a DGAT1 inhibitor with an IC₅₀ of 92.7 μM and can be extracted from Eleutherococcus senticosus. Guaiacylglycerol-8-O-4'-(sinapyl alcohol) ether can be utilized in research related to type II diabetes and obesity .

HY-112603A

AP5 sodium	Free Fatty Acid Receptor	Metabolic Disease
AP5 sodium is a potent, orall active, and selective GPR40 receptor agonist with a positive allosteric modulation of endogenous ligand (AgoPAM). AP5 sodium demonstrates rat and human inositol monophosphate (IP1) EC₅₀ values of 0.49 nM and 0.8 nM against the GPR40 receptor, respectively. AP5 sodium has the potential for type II diabetes research .

HY-W011303S

Phytosphingosine-d7 4-Hydroxysphinganine-d₇	Isotope-Labeled Compounds Fungal Free Fatty Acid Receptor Apoptosis Endogenous Metabolite	Infection Metabolic Disease Inflammation/Immunology Cancer
Phytosphingosine-d₇ (4-Hydroxysphinganine-d₇) is deuterium labeled Phytosphingosine. Phytosphingosine is a phospholipid with anti-inflammatory, antibacterial, and anti-cancer activities, which can induce apoptosis. Phytosphingosine is an immune regulator and can be used in the study of inflammatory skin diseases. Phytosphingosine is also an activator of GPR120 with an IC₅₀ value of 33.4 μM and can be used in the study of type II diabetes .

HY-113166R

Dodecanoylcarnitine (Standard) (-)-Lauroylcarnitine (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Dodecanoylcarnitine (Standard) is the analytical standard of Dodecanoylcarnitine (HY-113166). This product is intended for research and analytical applications. Dodecanoylcarnitine ((-)-Lauroylcarnitine) is a medium long-chain acylcarnitine, an intermediate product in key energy metabolic pathways of fatty acid β-oxidation and amino acids catabolism. The abnormal decrease in the Dodecanoylcarnitine levels indicats that mitochondrial fuel metabolism, including fatty acid oxidation is significantly disturbed. Changes in plasma concentrations of Dodecanoylcarnitine are not only associated with type II diabetes, but also with pre-diabetes status. Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease. Dodecanoylcarnitine deomonstrates high sensitivities and specificities in predicting asthma. Combined model of Decanoylcarnitine (HY-113069), Dodecanoylcarnitine, PC (16:0/0:0), and Asp Arg Pro can be used as a potential biomarker for the diagnosis of Yin-deficiency-heat syndrome .

HY-171302

GLP-1R/GIPR agonist-2	GLP Receptor	Metabolic Disease
GLP-1R/GIPR agonist-2 is a GIPR agonist. GLP-1R/GIPR agonist-2 potentiates GIP(1-42)-induced intracellular cAMP production in cells expressing human GIPR. GLP-1R/GIPR agonist-2 can be used for the research of type II diabetes mellitus .

HY-180489

GLP-1R agonist 38	GLP Receptor	Metabolic Disease
GLP-1R agonist 38 (page 15, compound 1) is a glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R agonist 38 can be used for the study of metabolic disorders and related diseases, including but not limited to type II diabetes mellitus (T2DM), obesity and non-alcoholic fatty liver disease (NASH) .

HY-108196R

PTP1B-IN-15 (Standard)	Reference Standards Phosphatase	Endocrinology
PTP1B-IN-15 (Standard) is the analytical standard of PTP1B-IN-15 (HY-108196). This product is intended for research and analytical applications. PTP1B-IN-15 is a potent and selective inhibitor of protein tyrosine phosphatase 1B (PTP1B). PTP1B-IN-15 has the potential for the research of type II diabetes and obesity .

HY-186072

NT-0527	NOD-like Receptor (NLR) Interleukin Related Cytochrome P450	Neurological Disease Metabolic Disease Inflammation/Immunology
NT-0527 is a selective, orally active, and brain-permeable NLRP3 inflammasome inhibitor. NT-0527 can specifically block the formation of the NLRP3 inflammasome, resulting in the reduction in the maturation and release of IL-1β, exhibit inhibition on CYP2C19. NT-0527 displays anti-inflammatory activity in the mouse LPS (HY-D1056) /ATP (HY-B2176)-induced peritonitis model. NT-0527 can be used for the research of neuroinflammatory disorders (Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis) and peripheral inflammatory disorders (type II diabetes, atherosclerosis, gout, etc.) associated with NLRP3 inflammasome .

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library	1,113 compounds
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage. The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes. MCE Anti-diabetic Compound Library owns a unique collection of 1,113 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Anti-diabetic Compound Library

1,113 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 1,113 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

HY-L208

Bile Acids Library

61 compounds

Bile acids are a class of amphiphilic molecules derived from the metabolic breakdown of cholesterol, primarily synthesized in the liver, and play a crucial role in the intestines. Based on their structural characteristics, bile acids are mainly divided into two categories: free bile acids (including Cholic acid, Deoxycholic acid, Chenodeoxycholic acid) and conjugated bile acids (including Glycocholic acid, Glycochenodeoxycholic acid, Taurocholic acid, etc.). Bile acids play a significant role in the pathophysiological research of liver and gastrointestinal diseases and are closely associated with the occurrence of metabolic diseases such as obesity, type II diabetes, non-alcoholic fatty liver disease, and atherosclerosis. Bile acids maintain metabolic balance within the body by regulating sugar metabolism, lipid metabolism, and amino acid metabolism, and they influence the activity of metabolism-related enzymes and transporters. In addition, Bile acids can also be used to construct a bile acid metabolism research platform, which helps to delve into the metabolic pathways and dynamic changes of bile acids in living organisms and aids in identifying new biomarkers for certain diseases.

MCE included 61 bile acids, including Cholic acid, Deoxycholic acid, Glycocholic acid, etc., which are effective tools for the study of liver and gallbladder diseases.

Cat. No.	Product Name	Target	Research Area

HY-P4767

Amylin (1-13) (human)	Amylin Receptor	Metabolic Disease
Amylin (1-13) (human) is a fragment and a residues within amyloid cores of Amylin (human IAPP). Amylin is a glucose-regulating hormone, deposits as amyloid fibrils in condition of type II diabetes (T2D). Amylin (1-13) (human) has no effect on firbl formation, as it cannot form fibrils by itself .

HY-P2501

Amylin (8-37), human	Amylin Receptor	Metabolic Disease
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus .

HY-P10312

SPN009	GLP Receptor	Metabolic Disease
SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC₅₀ of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W011303

Phytosphingosine 4 Publications Verification 4-Hydroxysphinganine	Infection Natural Products Human Gut Microbiota Metabolites Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Apoptosis Endogenous Metabolite Fungal Free Fatty Acid Receptor
Phytosphingosine is a phospholipid with anti-inflammatory, antibacterial, and anti-cancer activities, which can induce apoptosis. Phytosphingosine is an immune regulator and can be used in the study of inflammatory skin diseases. Phytosphingosine is also an activator of GPR120 with an IC₅₀ value of 33.4 μM and can be used in the study of type II diabetes .

HY-113166

Dodecanoylcarnitine 1 Publications Verification (-)-Lauroylcarnitine	Structural Classification Immune System Disorder Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Endocrine diseases Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Dodecanoylcarnitine ((-)-Lauroylcarnitine) is a medium long-chain acylcarnitine, an intermediate product in key energy metabolic pathways of fatty acid β-oxidation and amino acids catabolism. The abnormal decrease in the Dodecanoylcarnitine levels indicats that mitochondrial fuel metabolism, including fatty acid oxidation is significantly disturbed. Changes in plasma concentrations of Dodecanoylcarnitine are not only associated with type II diabetes, but also with pre-diabetes status. Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease. Dodecanoylcarnitine deomonstrates high sensitivities and specificities in predicting asthma. Combined model of Decanoylcarnitine (HY-113069), Dodecanoylcarnitine, PC (16:0/0:0), and Asp Arg Pro can be used as a potential biomarker for the diagnosis of Yin-deficiency-heat syndrome .

HY-109500

Masoprocol meso-Nordihydroguaiaretic acid; meso-NDGA	other families Classification of Application Fields Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	Lipoxygenase
Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .

HY-W011303R

Phytosphingosine (Standard) 4-Hydroxysphinganine (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Endogenous metabolite Source Classification	Reference Standards Apoptosis Endogenous Metabolite Fungal Free Fatty Acid Receptor
Phytosphingosine (Standard) is the analytical standard of Phytosphingosine. This product is intended for research and analytical applications. Phytosphingosine is a phospholipid with anti-inflammatory, antibacterial, and anti-cancer activities, which can induce apoptosis. Phytosphingosine is an immune regulator and can be used in the study of inflammatory skin diseases. Phytosphingosine is also an activator of GPR120 with an IC50 value of 33.4 μM and can be used in the study of type II diabetes[1][2][3][4].

HY-109500R

Masoprocol (Standard) meso-Nordihydroguaiaretic acid (Standard); meso-NDGA (Standard)	other families Phenols Polyphenols Plants Source Classification	Lipoxygenase Reference Standards
Masoprocol (Standard) is the analytical standard of Masoprocol. This product is intended for research and analytical applications. Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .

HY-N9153A

Guaiacylglycerol-8-O-4'-(sinapyl alcohol) ether	Monophenols Phenols Acanthopanax senticosus (Rupr. et Maxim.) Harms Plants Araliaceae Source Classification	Others
Guaiacylglycerol-8-O-4'-(sinapyl alcohol) ether is a DGAT1 inhibitor with an IC₅₀ of 92.7 μM and can be extracted from Eleutherococcus senticosus. Guaiacylglycerol-8-O-4'-(sinapyl alcohol) ether can be utilized in research related to type II diabetes and obesity .

HY-113166R

Dodecanoylcarnitine (Standard) (-)-Lauroylcarnitine (Standard)	Structural Classification Immune System Disorder Microorganisms Ketones, Aldehydes, Acids Disease markers Endocrine diseases Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Dodecanoylcarnitine (Standard) is the analytical standard of Dodecanoylcarnitine (HY-113166). This product is intended for research and analytical applications. Dodecanoylcarnitine ((-)-Lauroylcarnitine) is a medium long-chain acylcarnitine, an intermediate product in key energy metabolic pathways of fatty acid β-oxidation and amino acids catabolism. The abnormal decrease in the Dodecanoylcarnitine levels indicats that mitochondrial fuel metabolism, including fatty acid oxidation is significantly disturbed. Changes in plasma concentrations of Dodecanoylcarnitine are not only associated with type II diabetes, but also with pre-diabetes status. Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease. Dodecanoylcarnitine deomonstrates high sensitivities and specificities in predicting asthma. Combined model of Decanoylcarnitine (HY-113069), Dodecanoylcarnitine, PC (16:0/0:0), and Asp Arg Pro can be used as a potential biomarker for the diagnosis of Yin-deficiency-heat syndrome .

Cat. No.	Product Name	Chemical Structure

HY-W011303S

Phytosphingosine-d7

Phytosphingosine-d₇ (4-Hydroxysphinganine-d₇) is deuterium labeled Phytosphingosine. Phytosphingosine is a phospholipid with anti-inflammatory, antibacterial, and anti-cancer activities, which can induce apoptosis. Phytosphingosine is an immune regulator and can be used in the study of inflammatory skin diseases. Phytosphingosine is also an activator of GPR120 with an IC₅₀ value of 33.4 μM and can be used in the study of type II diabetes .

Cat. No.	Product Name		Classification

HY-113166

Dodecanoylcarnitine 1 Publications Verification (-)-Lauroylcarnitine		Cationic Lipids
Dodecanoylcarnitine ((-)-Lauroylcarnitine) is a medium long-chain acylcarnitine, an intermediate product in key energy metabolic pathways of fatty acid β-oxidation and amino acids catabolism. The abnormal decrease in the Dodecanoylcarnitine levels indicats that mitochondrial fuel metabolism, including fatty acid oxidation is significantly disturbed. Changes in plasma concentrations of Dodecanoylcarnitine are not only associated with type II diabetes, but also with pre-diabetes status. Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease. Dodecanoylcarnitine deomonstrates high sensitivities and specificities in predicting asthma. Combined model of Decanoylcarnitine (HY-113069), Dodecanoylcarnitine, PC (16:0/0:0), and Asp Arg Pro can be used as a potential biomarker for the diagnosis of Yin-deficiency-heat syndrome .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

type-II diabetes

Inhibitors & Agonists

Screening Libraries

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products